跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
許 明暉
教授
,
大數據科技及管理研究所
合聘教授
,
國際生技醫療管理博士學位學程
合聘教授
,
醫學院人工智慧醫療碩士在職專班
主治醫師
,
衛生福利部雙和醫院
成員
,
臺北醫學大學人工智慧醫療研究中心
成員
,
臺北醫學大學衛生福利政策研究中心
https://orcid.org/0000-0003-3607-2463
電子郵件
701056
tmu.edu
tw
12F, No. 172-1, Section 2, Keelung Rd, Da’an District, Taipei City, 106
h-index
1517
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2000
2025
每年研究成果
概覽
指紋
網路
專案
(10)
研究成果
(118)
類似的個人檔案
(12)
指紋
查看啟用 Min-Huei Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Influenza Vaccination
100%
Cohort Analysis
88%
Hazard Ratio
74%
COVID-19
73%
Cancer Risk
62%
Maturity Onset Diabetes of the Young
56%
Drug Therapy
55%
Malignant Neoplasm
50%
Chronic Kidney Disease
49%
Disease
43%
Apoplexy
42%
Breast Cancer
42%
Population Research
39%
Liver Cancer
38%
Randomized Controlled Trial
38%
Clinical Research
36%
Outpatient
36%
Diabetes
32%
Logistic Regression Analysis
31%
Antidiabetic Agent
30%
Lung Cancer
28%
Computerized Physician Order Entry
27%
Meta-Analysis
27%
Diabetes Mellitus
27%
Electronic Health Record
25%
Atrial Fibrillation
25%
Odds Ratio
25%
Electronic Patient Record
25%
Gout
24%
Ophthalmology
24%
Infection
22%
Patient with Type 2 Diabetes
22%
Eye Care
19%
Comorbidity
18%
Patient with Diabetes
18%
Case-Control Study
18%
Influenza Vaccine
17%
Diagnosis
17%
Cancer Therapy
17%
Disease Association
16%
Cardiovascular System
16%
Laboratory Test
16%
Glycon
15%
Retrospective Study
15%
Observational Study
14%
Proportional Hazards Model
14%
Emergency Department
14%
Patient with Hypertension
14%
Pancreas Cancer
14%
Patient Care
14%
Pharmacology, Toxicology and Pharmaceutical Science
Vaccination Policy
99%
Cohort Study
96%
Disease
79%
Malignant Neoplasm
64%
Lung Cancer
50%
Chronic Kidney Failure
49%
Comorbidity
48%
Clinical Research
42%
Breast Cancer
42%
Infection
33%
Non Insulin Dependent Diabetes Mellitus
28%
Influenza Vaccine
27%
Atrial Fibrillation
27%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
26%
Antidiabetic Agent
26%
Cancer Registry
25%
Gout
24%
Cancer Survival
24%
Benzodiazepine
24%
Heart Failure
24%
Prevalence
22%
Diabetes Mellitus
22%
Case-Control Study
19%
Coronavirinae
19%
Metformin
18%
Brain Hemorrhage
17%
Retrospective Study
16%
Epidermal Growth Factor Receptor
16%
Adverse Event
15%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Angiotensin Receptor Antagonist
14%
Brain Ischemia
14%
Pancreas Cancer
14%
Liver Cancer
14%
Chronic Obstructive Lung Disease
14%
Combination Therapy
14%
Observational Study
13%
Randomized Controlled Trial
13%
Syndrome
13%
Drug
12%
Disease Surveillance
12%
Proton Pump Inhibitor
12%
Drug-Drug Interaction
12%
Contrast Induced Nephropathy
12%
Adverse Drug Reaction
12%
Medication Error
12%
Colorectal Cancer
12%
Head Injury
12%
Aldosterone
12%
Urinary Tract Infection
12%
Nursing and Health Professions
Drug Therapy
42%
Disease
41%
National Health Insurance
33%
Outpatient
29%
Breast Cancer
24%
Influenza Vaccination
24%
Brain Cancer
24%
Personal Health Record
24%
Smart Card
24%
Area under the Curve
24%
Emergency Ward
22%
Receiver Operating Characteristic
22%
Malignant Neoplasm
18%
Consumer
17%
Adverse Drug Reaction
17%
Confidence Interval
17%
Electronic Medical Record
17%
Hazard Ratio
16%
Electronic Health Record
16%
Non Insulin Dependent Diabetes Mellitus
16%
Cohort Analysis
15%
Meta Analysis
15%
Hospital
14%
Acute Heart Infarction
14%
Prevalence
14%
Cancer Therapy
13%
Patient with Diabetes
13%
Health Care Delivery
13%
Vaccination Policy
13%
Syndrome
13%
Comorbidity
12%
Cancer Survival
12%
ST Segment Elevation
12%
Checklist
12%
Public Health Informatics
12%
Obstructive Lung Disease
12%
Eye Care
12%
Heart Infarction
12%
Metformin
12%
Dry Eye
12%
Patient with Type 2 Diabetes
12%
Telehealth
12%
Systematic Review
12%
Adverse Event
12%
Health Literacy
12%
Community Care
12%
Sympathectomy
12%
Hospital Readmission
12%
Mibolerone
12%
Diabetes Mellitus
12%
